Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Melanoma 1Leukemia, Hairy Cell 1Histiocytosis 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

tipifarnib 1ruxolitinib 1ripretinib 1peginterferon alfa-2a 1cobimetinib 1cc-486 1bemcentinib 1avelumab 1Vemurafenib 1Standard of Care 1Quality of Life 1Practice Guidelines as Topic 1Pentetic Acid 1Pemetrexed 1Patient Reported Outcome Measures 1Palliative Care 1PLX8394 1Nurse Clinicians 1Molecular Diagnostic Techniques 1Minocycline 1Ipilimumab 1Interferon alpha-2 1Injections 1In Situ Hybridization, Fluorescence 1Immunotherapy 1Imatinib Mesylate 1Heparin 1Fentanyl 1Drug Therapy 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × PLX8394 × Myeloid × Clear all
NCT02012231 2020-10-19

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

Fore Biotherapeutics

Phase 1 Terminated
5 enrolled
DermatologicEndocrineGastrointestinalHead & NeckMyeloidOther hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Leukemia, Hairy Cell, Melanoma, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis, Cholangiocarcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡